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ABSTRACT:
Phosphatase and tensin homolog (PTEN) loss is associated with genomic 
instability. APE1 is a key player in DNA base excision repair (BER) and an emerging 
drug target in cancer. We have developed small molecule inhibitors against APE1 
repair nuclease activity. In the current study we explored a synthetic lethal 
relationship between PTEN and APE1 in melanoma. Clinicopathological significance of 
PTEN mRNA and APE1 mRNA expression was investigated in 191 human melanomas. 
Preclinically, PTEN-deficient BRAF-mutated (UACC62, HT144, and SKMel28), PTEN-
proficient BRAF-wildtype (MeWo), and doxycycline-inducible PTEN-knockout BRAF-
wildtype MeWo melanoma cells were DNA repair expression profiled and investigated 
for synthetic lethality using a panel of four prototypical APE1 inhibitors. In human 
tumours, low PTEN mRNA and high APE1 mRNA was significantly associated with 
reduced relapse free and overall survival. Pre-clinically, compared to PTEN-proficient 
cells, PTEN-deficient cells displayed impaired expression of genes involved in DNA 
double strand break (DSB) repair. Synthetic lethality in PTEN-deficient cells was 
evidenced by increased sensitivity, accumulation of DSBs and induction of apoptosis 
following treatment with APE1 inhibitors. We conclude that PTEN deficiency is not only 
a promising biomarker in melanoma, but can also be targeted by a synthetic lethality 
strategy using inhibitors of BER, such as those targeting APE1.
INTRODUCTION
Base excision repair (BER) is a critical and highly 
conserved mechanism for the repair of damage induced 
by alkylation and oxidation of DNA, including by 
chemotherapy and ionising radiation [1]. Abasic sites (also 
known as apurinic/apyrimidinic or AP sites) are cytotoxic 
obligate repair intermediates generated during BER and 
processed by human apurinic/apyrimidinic endonuclease 1 
(APE1). APE1 cleaves the phosphodiester DNA backbone 
5’ to the AP site prior to further processing via either the 
short patch or the long patch BER pathway. Unrepaired AP 
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sites generate single strand breaks, which stall replication 
fork progression and induce DNA double strand breaks 
(DSBs) that are toxic to the cell at high density [2]. 
APE1 is a multifunctional protein [1, 3]. In addition 
to BER functions, it possesses N-terminus redox activity, 
which can activate pro-angiogenic and pro-survival 
transcription factors. APE1 also has roles in acetylation-
mediated gene regulation and RNA quality control [4]. 
SiRNA-mediated APE1 downregulation induces AP site 
accumulation and is associated with hypersensitivity to 
DNA damaging agents, including alkylators and ionising 
radiation [1]. Overexpression of APE1 confers resistance 
to these agents, both in vitro and in vivo [1]. Furthermore, 
exposure to alkylating agents causes upregulation 
of endogenous APE1 levels, suggesting a role in the 
development of treatment resistance [5]. APE1 expression 
in human tumours may have prognostic or predictive 
significance in patients [1]. 
In light of the evidence presented above, APE1 
is an emerging anti-cancer drug target. [1, 3]. We have 
initiated drug development programmes to identify novel 
inhibitors of APE1 DNA repair function [6-11]. Several 
of these compounds have shown promising preclinical 
activity, including the potentiation of the cytotoxicity of 
the alkylating agent temozolomide in cancer cell lines. 
More recently, we have demonstrated synthetic lethality 
of APE1 inhibition in BRCA-deficient cell systems [12], 
analagous to results observed with PARP inhibitors 
currently under development for treatment of HR-deficient 
cancer [13, 14]. 
Phosphatase and tensin homolog (PTEN) is 
a negative regulator of the anti-apoptotic PI3K/Akt 
pathway [15]. PTEN mutation is reported in 5-20% 
of primary melanomas, although PTEN mutation is 
more frequently seen in melanoma cell lines (30-50%) 
[16, 17]. Furthermore, transcriptional and translational 
repression of PTEN function has been reported in up 
to 65% of melanomas [18]. In addition to its inositol 
phosphatase function, PTEN has recently been implicated 
in the maintenance of genomic integrity [19-21]. PTEN-
null cells are associated with centromere-clustered 
chromosome breakages, possibly due to interaction 
with the centromeric protein CENP-C, which is vital for 
centromeric stability during mitosis. Additionally, PTEN 
might function as a transcriptional regulator of the critical 
homologous recombination (HR) protein RAD51 via the 
transcription factor Egr-1 [19-21]. Alternatively, PTEN 
loss may be associated with altered expression of the 
RAD51 paralogs [22] or impaired HR factor recruitment 
to DNA damage due to cell cycle checkpoint defects [20]. 
SUMOylation may be essential for PTEN DNA repair 
functions by directing nuclear PTEN localisation, with 
PTEN-null or non-SUMOylatable mutant cells exhibiting 
enhanced sensitivity to DNA damaging agents [23]. In 
keeping with these findings, PTEN -/- cells have been 
demonstrated to possess a HR defect that is associated 
with synthetic lethality following PARP inhibitor exposure 
[24]. However, although an association between RAD51 
deficiency, impaired HR and PTEN deficiency has 
been demonstrated in colorectal cancer cells [24] and 
endometrial cancer cells [25], the association was not 
demonstrated in prostate cancer models [22]. 
Loss of PTEN may promote melanoma development 
[26], possibly as a cooperating mutation with BRAF 
V600E [27]. Oncogenic BRAF V600 driver mutations 
have recently emerged as a key therapeutic target [28], 
leading to the development of vemurafanib [29]. Despite 
BRAF-targeted therapy, many patients eventually progress 
and succumb to the disease. Interestingly, a recent 
study has suggested that PTEN loss may contribute to 
BRAF inhibitor resistance in melanoma [30]. Therefore, 
development of therapeutic strategies targeting PTEN 
deficiency is highly desirable. In the current study, we 
hypothesised a synthetic lethal relationship between 
PTEN and APE1 in melanoma. We have measured mRNA 
expression of PTEN and APE1 in 191 human melanomas 
and correlated this with clinical and pathological factors. 
We have confirmed the utility of APE1 inhibitors in the 
presence of PTEN deficiency in melanoma cell lines.
RESULTS
Prognostic significance of PTEN mRNA and APE1 
mRNA expression in human melanomas 
Patient demographics of the 191 cases are 
summarized in Supplementary Table S1. The 
clinicopathological association data are summarised 
in Supplementary Table S2. Relapse free and overall 
survival data are summarized in Supplementary Table S3. 
Low PTEN and high APE1 mRNA expression associated 
with presence of vascular invasion (p=0.05) and high 
mitotic rate (p=0.4), respectively. In the whole cohort 
(n=191), low PTEN mRNA expression was significantly 
associated with poor relapse free survival and overall 
survival (Supplementary Table S3 and Figure 1A). High 
APE1 mRNA expression was also significantly associated 
with poor relapse free survival and overall survival 
(supplementary Table S3 and Figure 1B) in the whole 
cohort. When PTEN and APE1 are considered together, 
patients with tumours that exhibit high PTEN and low 
APE1 mRNA expression have a significantly better 
prognosis compared to tumours that have low PTEN/high 
APE1 mRNA expression or low PTEN/low APE1 mRNA 
expression or high PTEN/high APE1 mRNA expression 
(Figure 1C). 
Given the evidence in murine models that low PTEN 
and BRAF V600 mutations results in development of 
metastatic melanoma [27], we conducted an exploratory 
analysis based on PTEN mRNA expression and BRAF/
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NRAS status. None of the patients with BRAF V600 
mutation had received vemurafanib (BRAF inhibitor) 
therapy. In tumours that had no BRAF or NRAS mutation, 
low PTEN was significantly associated with poor overall 
survival [HR (95%CI)=0.27 (0.12, 0.64), p=0.003] 
(Figure 1D). In tumours that have BRAF mutation (Figure 
1B) [HR (95%CI)=0.81 (0.46, 1.43), p=0.47] and in NRAS 
mutants, low PTEN level did not significantly influence 
prognosis (Figure 1C) [HR (95%CI)=0.88 (0.29, 2.69), 
p=0.82]. Taken together, the data suggest that PTEN 
deficiency is a promising prognostic marker in BRAF wild 
type melanomas. 
PTEN-deficient melanoma cell lines exhibit 
altered DSB repair protein levels
 The emerging role of PTEN in DNA repair [23] 
and the association between low PTEN and impaired 
DNA DSB repair [19-21] implies that PTEN- deficient 
melanoma cells with defective DSB repair may be more 
reliant upon BER to maintain genomic stability. To 
investigate the hypothesis that PTEN loss is associated 
with impaired HR, DSB repair protein levels were 
examined in melanoma cell lines. MeWo (BRAF wildtype, 
NRAS wildtype), SkMel28 (BRAF V600E mutant, 
NRAS wildtype), HT144 (BRAF V600E mutant, NRAS 
wildtype) and UACC62 (BRAF V600E mutant, NRAS 
wildtype) melanoma cell lines were screened for PTEN 
protein. As shown in Figure 2A and 2B, western blot 
analysis confirmed high PTEN protein levels in MeWo 
cells. UACC62 and HT144 cells demonstrate an almost 
complete absence of PTEN protein; SkMel28 exhibits 
an intermediate level. All four cell lines are proficient in 
APE1 expression. In keeping with previous studies [21, 
24], PTEN-deficient HT144 and UACC62 melanoma 
cells were also RAD51-deficient. RAD51 level was also 
lower in SkMel28 cells compared to MeWo. However, 
Fraser et al. did not observe RAD51 deficiency in 
PTEN-deficient prostate cancer cells [22]. Therefore, for 
additional clarification, we explored protein levels of other 
key DSB repair factors. As shown in Figure 2A and 2B, 
PTEN-deficient cells exhibited consistently lower levels 
of a number of DSB repair proteins compared to PTEN-
proficient MeWo. 
We proceeded to generate a doxycycline inducible 
PTEN-knockdown, BRAF-proficient MeWo cell 
line. Figure 2C and 2D demonstrates time-dependent 
knockdown of PTEN protein expression following 
doxycycline induction of lentiviral shRNA transduced 
Figure 1: Kaplan Meier curves showing overall survival in melanoma. A. Whole cohort (PTEN mRNA high and low, p=0.01). 
B. Whole cohort (APE1 mRNA high and low, p=0.002). C. Whole cohort (PTEN and APE1 m RNA combined high and low, p=0.0009). D. 
Tumours with no BRAF/NRAS mutations (PTEN mRNA high and low, p=0.003). E. Tumours with BRAF V600E mutation (PTEN mRNA 
high and low, p=0.36). F. Tumours with NRAS mutations (PTEN mRNA high and low, p=0.68). 
Oncotarget3276www.impactjournals.com/oncotarget
into MeWo cells. By day 7, PTEN protein level was 
reduced to ~50% baseline, reaching >90% by day 14. 
We confirmed reduced PTEN transcript production at day 
21 by qRT-PCR (Figure 2D). Western blot examination 
confirmed that levels of a number of DSB repair proteins 
were reduced in PTEN-knockdown cells compared to non-
induced controls (Figure 2E and 2F). Taken together, these 
data confirm that PTEN loss is associated with reduced 
DSB repair protein levels in melanoma cells. 
PTEN-deficient melanoma cells have dysregulated 
DNA repair mRNA expression
To investigate DNA repair expression at the mRNA 
level, we profiled a panel of 88 DNA repair genes in 
MeWo, PTEN-knockdown MeWo, SkMel28, HT144 
and UACC62 melanoma cells using the RT2 Profiler 
DNA Repair PCR array. Significantly reduced mRNA 
expression of several HR repair genes was observed in 
PTEN-deficient cells (summarised in Supplementary Table 
S5 and Supplementary Figure S1). This included several 
repair factors that have previously been implicated in 
PTEN deficiency, including RAD51 [21, 24, 37], MRE11 
[22], and the RAD51 paralogs RAD51B, RAD51C, 
RAD51D, XRCC2 and XRCC3 [38]. We also observed 
low expression of a number of genes involved in non-
homologous end joining(NHEJ), as well as nucleotide 
excision repair(NER) and mismatch repair(MMR). 
Interestingly, significantly increased mRNA expression 
of ATM, CCNH and DDB2 was also observed. Taken 
together, the data suggest that PTEN-deficient melanoma 
cells have complex patterns of DNA repair dysregulation 
with consistent downregulation of genes involved in DSB 
repair. 
Figure 2: A. Representative Western blots of PTEN and selected DNA repair proteins in human melanoma cell lines. B. Quantification 
of PTEN and selected DNA repair factor protein levels in melanoma cell lines. C. Generation of doxycycline-inducible PTEN knockdown 
MeWo cells. Following lentiviral transduction, continuous doxycycline exposure induced PTEN shRNA expression. Whole cell lysates 
were examined for PTEN protein levels every 7 days, with almost complete absence observed by day 21. This was confirmed by mRNA 
analysis by qRT-PCR (D). E. Representative Western blots and quantification (F) of PTEN and selected DNA repair proteins in control and 
PTEN knockdown (KD) cell line. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to control cells.
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PTEN-deficient melanoma cells are sensitive to 
APE1 inhibitors
As PTEN-deficient cells exhibited differential 
expression of HR factors, blockade of BER through 
APE1 inhibition could lead to synthetic lethality. To 
test this hypothesis, we conducted studies in clinically 
relevant PTEN-deficient and PTEN-proficient melanoma 
cells using a panel of APE1 inhibitors. Four prototypical 
APE1 inhibitors were evaluated (chemical structures are 
shown in Supplementary Figure S2) in MeWo, SKMel28, 
UACC62, HT144 and PTEN-knockdown MeWo cells. 
We first confirmed target inhibition using the ARP assay. 
A significant accumulation of AP sites in genomic DNA 
was demonstrated following 2, 4 and 8 hours exposure to 
inhibitor 1, inhibitor 2, inhibitor 3 or inhibitor 4 (Figures 
3A-D). We then evaluated whether these inhibitors could 
induce selective cytotoxicity in PTEN-deficient cells using 
clonogenic survival assays. Treatment with each inhibitor 
resulted in reduced survival of PTEN-deficient SKMel28, 
UACC62, and HT144 cells in comparison to PTEN-
proficient MeWo cells (Figure 3E-3H). Similarly, PTEN-
knockdown MeWo cells exhibited significantly increased 
sensitivity to APE1 inhibitor treatment compared to 
control cells (Figures 4A-4D). 
To confirm that selective toxicity is due to APE1 
inhibtion, we utilised the indirect APE1 inhibitor 
methoxyamine. Methoxyamine binds irreversibly to AP 
sites in DNA [36], preventing APE1 from processing 
the adducted AP lesions. Figure 5E demonstrates that 
methoxyamine is more lethal to PTEN-deficient SKMel28, 
UACC62, and HT144 cells than to PTEN-proficient MeWo 
cells. Similarly, PTEN-knockdown MeWo cells were more 
sensitive to methoxyamine compared to PTEN-proficient 
control cells (Figure 4F). To further establish whether this 
selective cytotoxicity was due to obstruction of BER, we 
investigated NU1025, a PARP inhibitor that blocks the 
BER-related single strand break repair (SSBR) pathway 
[39]. Figure 4G demonstrates the increased toxicity of 
Figure 3: Aldehyde reactive probe assay confirming target inhibition in MeWo, SkMel28, UACC62 and HT144 cells 
treated with inhibitor -1 (A), inhibitor -2 (B), inhibitor -3 (C) and inhibitor -4 (D). Clonogenic survival assays in MeWo, 
SkMel28, UACC62 and HT144 cells treated with inhibitor-1 (E), inhibitor-2 (F), inhibitor-3 (G) and inhibitor-4 (H). Inhibitors were added 
at the indicated concentrations (see methods for details). * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to MeWo (PTEN-
wildtype).
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NU1025 in PTEN-deficient SKMel28, UACC62 and 
HT144 cells compared to PTEN-proficient MeWo cells. 
This result was repeated in PTEN-knockdown MeWo 
cells, which were more sensitive to NU1025 (Figure 4H) 
than PTEN-proficient MeWo cells. The data is consistent 
with a previous study in which PTEN-deficient colorectal 
cells were found to exhibit increased sensitivity to PARP 
inhibition [24].
Selective sensitivity of PTEN-deficient melanoma 
cells following APE1 inhibition results from 
increased DNA damage accumulation
The clonogenic survival data provides compelling 
evidence for selective toxicity of APE1 inhibitors in 
PTEN-deficient melanoma cells. To provide mechanistic 
evidence that APE1 inhibition leads to synthetic 
lethality in PTEN-deficient cells, we investigated the 
functional consequence of APE1 inhibitor treatment. The 
neutral COMET assay detects single and double strand 
breaks(DSBs) in DNA. Figures 5A-5I summarise the 
results for MeWo, SKMel28, UACC62, HT144 and PTEN-
knockdown MeWo cells treated with APE1 inhibitors. 
Mean tail moment was increased in all samples after APE1 
inhibitor exposure compared to pre-treatment samples, and 
was significantly higher in PTEN-deficient cells at 2, 4, 
and 8 hours in comparison to PTEN-proficient cells, with 
damage persisting to 48 hours. The data demonstrates that 
PTEN-deficient cells accumulate greater numbers of DNA 
breaks after exposure to an APE1 inhibitor compared to 
PTEN-proficient cells. 
Phosphorylation of H2AX at serine 139 (γH2AX) 
is induced by DSBs, and can be used as a marker of 
DSB formation. Following inhibitor exposure, γH2AX 
immunocytochemistry was performed in MeWo, 
Figure 4: Clonogenic survival assays in control MeWo cells and PTEN knockdown (KD) MeWo cells treated with 
inhibitor-1 (A), inhibitor-2 (B), inhibitor-3 (C) and inhibitor-4 (D). Clonogenic survival assays in MeWo, SkMel28, UACC62 
and HT144 cells treated with methoxyamine (E). Clonogenic survival assays in control MeWo cells and PTEN knockdown (KD) MeWo 
cells treated with methoxyamine (F). Clonogenic survival assays in MeWo, SkMel28, UACC62 and HT144 cells treated with NU1025 
(G). Clonogenic survival assays in control MeWo cells and PTEN knockdown (KD) MeWo cells treated with NU1025 (H). Inhibitors were 
added at the indicated concentrations (see methods for details). * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to MeWo 
(PTEN-wildtype).
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SKMel28, UACC62, HT144 and PTEN-knockdown 
MeWo cells. As shown in Figures 6A-6I, the percentage 
of cells with more than six γH2AX foci following inhibitor 
exposure was significantly higher in PTEN-deficient cells 
compared to PTEN-proficient control cells. These data 
provide additional evidence that PTEN-deficient cells 
accumulate DSBs at an increased rate after exposure to an 
APE1 inhibitor relative to PTEN-proficient MeWo cells. 
DSB accumulation activates a complex cell cycle 
checkpoint response that may result in eventual induction 
of apoptosis. Apoptosis detection by FITC-annexin V flow 
cytometric analysis was therefore performed in MeWo, 
SKMel28, UACC62, HT144 and PTEN-knockdown 
MeWo cells following exposure to inhibitor 1, inhibitor 2, 
inhibitor 3, or inhibitor 4 for 24 or 48 hours. As shown in 
Figure 7A-7I, the percentage of cells undergoing apoptosis 
following APE1 inhibitor exposure was significantly 
higher in PTEN-deficient cells in comparison to PTEN-
proficient MeWo cells. 
Taken together, these functional studies provide 
compelling evidence that APE1 inhibition induces a 
synthetic lethal response in PTEN-deficient cells by 
causing accumulation of abasic sites and subsequent 
strand breaks, and ultimately the induction of apoptosis. 
DISCUSSION
PTEN is a key regulator of the anti-apoptotic PI3K/
Akt pathway [15], and emerging evidence suggests a role 
in DNA repair [19-21]. The role of PTEN in the regulation 
of RAD51 remains controversial [24]. However, a number 
of recent studies provide compelling evidence that nuclear 
PTEN may have essential roles in DNA repair [40, 41], 
and that PTEN deficiency may be targeted in a synthetic 
lethality approach by inhibitors of SSBR [24]. Our 
primary hypothesis is that this synthetic lethality approach 
may be applied to PTEN-deficient melanomas using BER 
inhibitors such as those targeting APE1. We initially 
Figure 5: Neutral comet assay was performed at various time points after APE1 inhibitor exposure as indicated in 
methods. A. Example of increased DNA damage comet ‘tail’ in PTEN-deficient HT144 compared to MeWo cells following 24 hours 
exposure to inhibitor-1. Significantly increased mean tail moment was observed in PTEN-deficient SkMel28, UACC62 and HT144 cells 
compared to MeWo cells following treatment with inhibitor-1 (B), inhibitor-2 (C), inhibitor 3 (D) and inhibitor 4 (E). Similarly, significantly 
increased mean tail moment was observed in PTEN knockdown (KD) MeWo cells compared to control MeWo cells treated with inhibitor-1 
(F), inhibitor-2 (G), inhibitor 3 (H) and inhibitor 4 (I). ** p<0.01, *** p<0.001, compared to MeWo (PTEN-wildtype).
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investigated the clinicopathological significance of PTEN 
mRNA and APE1 mRNA in melanoma. Low PTEN was 
associated with poor survival overall but the effect was 
absent in BRAF and NRAS-mutated tumours, and only 
statistically significant in tumours without BRAF or NRAS 
mutations. This may be related to the complex tumour-
suppressing function of PTEN, including its roles as a 
negative regulator of the anti-apoptotic PI3K/Akt pathway 
and in DNA repair regulation. That the influence of PTEN 
expression on prognosis was more pronounced in tumours 
without BRAF or NRAS mutations is a new observation, 
and suggests that PTEN loss may be a key biomarker in 
BRAF-wildtype tumours. Taken together, the clinical 
data are consistent with pre-clinical study that implicates 
PTEN loss in melanoma progression [26]; however, the 
relatively small patient numbers in the various subgroups 
is a limitation of our study. Our finding that high APE1 
mRNA is associated with poor survival in melanoma is 
supported by previous studies [42] and provides additional 
evidence for targeting APE1 in melanoma. 
The success of PARP inhibitors in BRCA-deficient 
breast and ovarian tumours [13, 14] implies that a 
synthetic lethality approach may be an attractive strategy 
in melanomas with DSB repair deficiency. PTEN-
deficient melanoma cells with defective DSB repair may 
be reliant upon BER as a frontline defence to prevent 
damage accumulation, replication fork collapse, DSB 
formation and consequent cell death. Thus, blockade of 
BER through APE1 inhibition could lead to synthetic 
lethality in PTEN-deficient cells. To test this hypothesis, 
we first profiled PTEN-deficient and PTEN-proficient 
melanoma cells for DNA repair factor expression, finding 
that expression of several genes involved in HR was 
impaired at protein and mRNA level in PTEN-deficient 
cells. In addition we observed downregulation of genes 
involved in NHEJ, NER, MMR and MGMT. Given the 
role of PTEN in the regulation of HR expression as well 
as in HR recruitment to sites of DNA damage [19-21], 
it is perhaps not surprising that genomic instability in 
PTEN-null cells may, over a period of time, eventually 
Figure 6: A. γH2AX immunocytochemistry following 24 hours inhibitor-1 exposure demonstrates increased foci in PTEN-deficient 
HT144 cells compared to PTEN-wildtype MeWo. Significantly increased γH2AX foci was observed in PTEN-deficient SkMel28, UACC62 
and HT144 cells compared to MeWo cells following 24 hours treatment with inhibitor-1 (B), inhibitor-2 (C), inhibitor-3 (D) or inhibitor-4 
(E). Similar significantly increased γH2AX foci was observed in PTEN knockdown (KD) MeWo cells compared to control MeWo cells 
following 24 hours treatment with inhibitor-1 (F), inhibitor-2 (G), inhibitor-3 (H) or inhibitor-4 (I). * p<0.05, ** p<0.01, *** p<0.001, 
compared to MeWo (PTEN-wildtype).
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lead to acquisition of new defects in other DNA repair 
pathways. Recent studies that positively link PTEN 
with NER [43], MMR [44], and MGMT expression 
[45] suggests that such a mechanism may be operating 
in cells, but detailed mechanistic studies are required to 
confirm this hypothesis. An interesting observation across 
PTEN-deficient cell lines was the loss of BRCA1 protein 
expression, consistent with previous evidence in UACC62 
melanoma cells (http://cancer.sanger.ac.uk/cancergenome/ 
projects/cosmic/). This observation is also consistent with 
a recent study in breast cancer, wherein high frequency 
of PTEN loss was observed in BRCA1-associated breast 
tumours [46]. In a separate study, PTEN loss was found to 
be a predictor of BRCA1 germ-line mutations in women 
with early onset breast cancer [47]. Taken together, this 
evidence suggests a possible functional link between 
PTEN and BRCA1 in melanomas. These observations, 
however, require detailed mechanistic studies to confirm 
functional interactions between PTEN and BRCA1. 
PTEN-deficient melanoma cells were shown in 
the current study to be sensitive to APE1 inhibitors. 
Similar hypersensitivity observed following exposure to 
the PARP inhibitor NU1025 is consistent with previous 
observations using PTEN-deficient colorectal cells [24]. 
We have concluded that the interrelationship between 
BER and PTEN may be a valid therapeutic target in 
melanoma for the following reasons: a) PTEN-deficient 
cells are sensitive to APE1 repair domain inhibitors; b) 
PTEN-deficient cells are sensitive to methoxyamine, 
an indirect inhibitor of APE1; c) PTEN-deficient cells 
are sensitive to the PARP inhibitor NU1025; and d) 
upon APE1 inhibitor treatment, PTEN-deficient cells 
accumulate DNA DSBs, resulting in the induction of 
apoptosis. It should be noted that the observed level of 
apoptosis in PTEN-deficient cells following inhibitor 
exposure is lower than may be predicted from survival 
analyses using clonogenic assays. Although apoptotic cell 
accumulation may occur over a period of time following 
Figure 7: A. Apoptosis detection by FITC-annexin V flow cytometric analysis demonstrates an increased apoptotic fraction in HT144 
following 48 hours exposure to inhibitor-1, as observed by increased FITC-Annexin V staining in upper and lower right quadrants. 
Significantly increased apoptotic fraction was observed in PTEN-deficient SkMel28, UACC62 and HT144 cells compared to MeWo cells 
following 48 hours treatment with indicated concentrations of inhibitor-1 (B), inhibitor-2 (C), inhibitor-3 (D) or inhibitor-4 (E). Similar 
significantly increased apoptotic fraction was observed in PTEN knockdown (KD) MeWo cells compared to control MeWo cells following 
48 hours treatment with inhibitor-1 (F), inhibitor-2 (G), inhibitor-3 (H) or inhibitor-4 (I). * p<0.05, ** p<0.01, *** p<0.001, compared to 
MeWo (PTEN-wildtype).
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chronic exposure to APE1 inhibitor, another possible 
explanation is ‘synthetic sickness’, a synthetic lethal-type 
relationship wherein the overall outcome is reduced fitness 
rather than cellular lethality [48]. Accumulation of DNA 
damage, including specific DSB accumulation, has been 
associated with the induction of cellular senescence [49]. 
More recently, PTEN loss has also been shown to induce 
a senescent phenotype [50]. Therefore we speculate that 
DSB accumulation in PTEN-deficient cells following 
APE1 inhibition, besides induction of apoptosis, may also 
drive the cell population into senescence, contributing to 
reduced clonogenicity. Although further study is required 
to assess for definitive evidence of senescence induction 
in this setting, our data raise the intriguing possibility of a 
future avenue for pro-senescence therapy.
In conclusion, our study provides the first evidence 
that blockage of BER by APE1 inhibition has attractive 
potential for a novel therapeutic approach in PTEN-
deficient melanomas. This strategy could have significant 
translational applications for personalised therapy in 
melanoma patients. 
METHODS
Clinical study
Gene expression analysis: Whole genome gene 
expression (~30,000 probes) was measured using 
Illumina DASL approach in 240 formalin fixed primary 
melanoma tumours from Leeds Melanoma Cohort [31], 
including 29 duplicates to serve in QC checks. After 
QC, the cohort contained 191 patients including 106 
who had relapsed and 101 who had died. Histology data 
were derived from clinical histopathology reports. For a 
subset of tumors diagnostic H+E slides were reviewed 
by a dermatopathologist (Dr Andy Boon (Cohort study) 
to standardize reporting across the specimens. BRAF and 
NRAS mutation status was also available for 182 of these 
tumours, derived using pyrosequencing as previously 
described [32]. The study was approved by the National 
Research ethics committee (UK).
Statistical analyses
 Data was normalised using background correction 
and robust spline smoothing with Lumi R package. The 
associations between PTEN and APE1 mRNA expressions 
and histological factors were assessed using linear and 
logistic regression of log2 transformed gene expression 
data. Separate and joint effects of PTEN and APE1 
mRNA expressions on relapse-free and overall survival 
was tested. Expression data were used as continuous 
after log2 transformation and after dichotomisation using 
expression cut-offs determined using X-Tile software [33]. 
In stratified analysis, Cox proportional hazard model was 
applied on dichotomized PTEN expression stratifying on 
presence of BRAF mutations, NRAS mutations and no 
mutations.
Cell lines
Clinically relevant previously well-characterised 
melanoma cell lines were chosen for the pre-clinical 
study. MeWo is a BRAF wildtype and NRAS wildtype 
melanoma cell line. SkMel28, HT144 and UACC62 
are BRAF V600 mutant and NRAS wildtype melanoma 
cells lines (http://cancer.sanger.ac.uk/cancergenome/ 
projects/cosmic/). 
Generation of doxycycline inducible PTEN 
knockdown MeWo cell line by lentiviral shRNA 
transduction
TRIPZ shRNA plasmid against PTEN was purchased 
from Thermo Scientific (Clone ID: V3THS_312158: 
5’-GGAAAGAATCAAGGAGG-3’, Loughborough, UK). 
Lentiviral production was performed per the supplied 
protocol using the Lenti-X high-titer lentiviral packaging 
system in Lenti-X 293T cells (Clontech, Mountain View, 
USA). After 48 hours incubation, lentivirus-containing 
supernatant was harvested and applied to MeWo cells at an 
MOI of 1 or 3. Once stable in culture, puromycin selection 
was initiated at a concentration of 1μg/ml. To induce 
shRNA expression, doxycycline was added to culture 
medium at a concentration of 0.5-1μg/ml and replaced 
every 72 hours. Confirmation of reduced transcript 
production by qRT-PCR was performed on an Applied 
Biosystems 7500 FAST cycler using Qiagen PCR primers 
against PTEN [Qiagen Quantitect primers (HS_PTEN_4_
SG and HS_GAPDH_1_SG)]. Absence of PTEN protein 
expression was confirmed on Western blot.
qRT-PCR analysis of DNA repair gene expression 
in melanoma cell lines
RNA was extracted from melanoma cell lines using 
the RNeasy Mini Kit (Qiagen) and quantified using a 
microvolume spectrophotometer. cDNA synthesis was 
performed using the RT2 First Strand Kit (Qiagen). Real 
time PCR was carried out on an Applied Biosystems 
75000 FAST cycler in a commercially available 96-well 
plate format, allowing assessment of 88 DNA repair 
genes simultaneously (RT2 Profiler DNA Repair PCR 
Array). Threshold cycle was calculated for each well and 
exported to online software for further analysis (www.
SABiosciences.com/pcrarraydataanalysis.php). All 
experiments were performed in triplicate.
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Western blot analysis 
Primary antibody details are summarised in 
Supplementary Table S4. Protein expression was 
examined by infrared dye-labelled secondary antibody 
(Li-Cor, 1:15000 dilution) detected by Li-Cor Odyssey 
Scanner. All experiments were performed in triplicate.
APE1 inhibitors and other compounds
We have previously identified a number of 
APE1 inhibitors. [34, 35] Cell biology experiments 
performed here utilised structural analogues of N-(4-
fluorophenyl)-2-[4-phenylsulfonyl-2-(p-tolyl)oxazol-5-
yl]sulfanyl-acetamide (previously characterised in [12]: 
N-(4-fluorophenyl) -2- (2-phenyl-4- phenylsulfonyl-1,3-
oxazol-5-yl]sulfanyl-acetamide (Inhibitor-1) and N-(4-
fluorophenyl)-2-(2-phenyl-4-phenylsulfonyl-oxazol-
5-yl)sulfanyl-acetamide (Inhibitor-2), purchased from 
ChemDiv. Additional inhibitors previously identified 
by Rai et al. [35] were synthesised by the National 
Institutes of Health (NIH) Chemical Genomics Center 
(NCGC): N-(3-(benzo[d]-thiazol-2-yl)-6-isopropyl-
4,5,6,7-tetrahydrothieno[2,3-c]-pyridin-2-yl)acetamide 
(Inhibitor-3) and its analogue N-(3-(benzo[d]thiazol-2-
yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl)acetamide 
(Inhibitor-4). APE1 inhibitors investigated here are 
highly potent and specific for APE1. They do not bind to 
DNA and have no activity against E. coli endonuclease 
IV (a functional homolog with no sequence or structural 
homology to APE1). IC50 for APE1 endonuclease activity 
inhibiton in purified protein fluoresence based biochemical 
assays are as follows; inhibitor 1= 0.2µM, inhibitor 2= 
0.1µM , inhibitor 3= 2µM and inhibitor 4=3.3µM . The 
compounds also block AP site cleavage activity in HeLa 
whole cell extract assays, and potentiate the cytotoxicity 
of alkylating agents in cancer cell lines [34, 35]. Molecular 
modelling studies indicate that these APE1 inhibitors dock 
onto the active site of APE1 [8, 34]. Methoxyamine, a 
non-specific indirect inhibitor of APE1, binds irreversibly 
to AP sites in DNA [36] and prevents APE1 (and 
endonuclease IV) from processing the adducted AP lesion. 
Methoxyamine (indirect APE1 inhibitor) was purchased 
from Sigma. NU1025 (PARP inhibitor) was purchased 
from Tocris Bioscience. 
Clonogenic survival assay 
Cell lines were plated into 6-well plates at a density 
of 200-400 cells per well. Cells were allowed to adhere 
for 4 hours, after which inhibitory compound was added at 
varying concentrations. Cells were incubated for 14 days 
under normal incubator conditions. After this time, media 
was discarded and cells were stained using 10% crystal 
violet in 70% aqueous ethanol to allow quantification 
of colony number. All experiments were performed in 
triplicate.
Aldehyde Reactive Probe (ARP) assay 
Cell-based ARP assay was performed according to 
the manufacturer’s instructions (Abcam). Cells were plated 
at high density in a 96-well plate, allowed to grow for 24 
hours, then treated with inhibitor. Results were presented 
as percent increase in fluorescence as a surrogate for AP 
site accumulation.
Neutral COMET assay
Cell lines were plated into 6cm petridishes at a 
density of 105 cells per plate. Cells were allowed to adhere 
for 24 hours, after which time inhibitory compound was 
added at a single concentration. Cells were harvested at 0, 
2, 4, 8, 24 and 48 hour time points, and neutral COMET 
assay was performed as described previously [12]. All 
experiments were performed in triplicate.
γH2AX immunocytochemistry
Cell lines were seeded onto sterile coverslips in 
6-well plates at a density of 105 cells per well. Cells were 
allowed to adhere for 24 hours, after which time inhibitory 
compound was added. After 24 hours exposure, γH2AX 
immunocytochemistry was performed [12]. The number 
of γH2AX foci per nucleus was determined in 100 cells 
per slide. Nuclei containing more than 6 γH2AX foci were 
considered positive. All experiments were performed in 
triplicate.
Apoptosis detection by FITC-annexin V flow 
cytometric analysis
Cell lines were plated into 6-well plates at a 
density of 5 x 105 cells per well. Cells were allowed 
to adhere for 24 hours, after which time inhibitory 
compound was added. After 24 hours exposure, cells were 
gently trypsinised, washed twice in ice-cold PBS, and 
resuspended in Annexin V binding buffer (FITC Annexin 
V Apoptosis Detection Kit I, BD Pharmingen). Cells 
were incubated for 15 minutes in the dark with FITC-
Annexin V and propidium iodide (PI), then analysed by 
flow cytometry using a BC Accuri C6 Flow Cytometer. 
The percentage of induced apoptosis (FITC-Annexin 
V positive, PI negative and FITC-Annexin V positive, 
PI positive) was determined by comparison to a control 
population of untreated cells. All experiments were 
performed in triplicate [12].
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